Table 4.
Thyroid clinical entities in the general population of Rhea mother-child cohort based on: (i) the manufacturer's and (ii) the derived reference limits.
| Trimester | Reference limits | Normal thyroid function n (%)a | Subclinical hypothyroidism n (%)b | Clinical hypothyroidism n (%)c | Subclinical hyperthyroidism n (%)d | Clinical hyperthyroidism n (%)e |
|---|---|---|---|---|---|---|
| 1st | Manufacturer | 386 (84.3) | 6 (1.3) | 0 (0) | 48 (10.5) | 7 (1.5) |
| Rhea cohort | 371 (81.0) | 31 (6.8) | 0 (0) | 1 (0.2) | 10 (2.2) | |
| 2nd | Manufacturer | 680 (86.6) | 18 (2.3) | 1 (0.1) | 61 (7.7) | 1 (0.1) |
| Rhea Cohort | 653 (82.2) | 47 (5.9) | 0 (0) | 18 (2.3) | 9 (1,1) |
aTSH between reference limits and free T4 between reference limits.
bTSH over the upper limit of reference limits and free T4 between reference limits.
cTSH over the upper limit of reference limits and free T4 under the lower limit of reference limits.
dTSH under the lower limit of reference limits and free T4 between reference limits.
eTSH under the lower limit of reference limits and free T4 over the upper limit of reference limits.